Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed gastric or gastroesophageal junction adenocarcinoma
• * Locally advanced unresectable or metastatic disease
• Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10mm by spiral CT scan
• * Bone metastases, ascites, or pleural effusions are not considered measurable disease
• * Evaluable disease must be present outside previously irradiated field
• No CNS or brain metastases
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• SWOG 0-1
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Hemoglobin ≥ 10 mg/dL
• No evidence of bleeding diathesis or coagulopathy
• Hepatic
• AST and ALT ≤ 2.5 times upper limit of normal (ULN)
• Alkaline phosphatase ≤ 2.5 times ULN
• Bilirubin ≤ ULN
• INR \< 1.5
• Renal
• Creatinine \< 2.0 mg/dL
• Urine protein:creatinine ratio \< 1.0
• Cardiovascular
• No history of deep venous thrombosis requiring anticoagulation
• No active angina
• No myocardial infarction within the past year
• No cerebrovascular accident within the past year
• No uncontrolled hypertension (systolic blood pressure \[BP\] \> 170 mm Hg and/or diastolic BP \> 100 mm Hg) despite medical management
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 3 months after completion of study treatment
• No peripheral neuropathy \> grade 1
• No history of allergy to any of the study drugs or drugs formulated with polysorbate 80
• No known HIV infection
• No active peptic ulcer disease
• No serious non-healing wound, ulcer, or bone fracture
• No unresolved bacterial infection requiring antibiotics
• No other active malignancy within the past 3 years except for cancers that have been treated with a curative intent
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No concurrent immunotherapy
• Chemotherapy
• No prior chemotherapy for gastric cancer unless disease relapsed \> 6 months after completion of non-taxane adjuvant chemotherapy
• No other concurrent chemotherapy
• Endocrine therapy
• Not specified
• Radiotherapy
• See Disease Characteristics
• At least 3 weeks since radiotherapy
• Surgery
• At least 4 weeks since prior surgery or open biopsy (except indwelling venous catheter placement)
• No concurrent surgery
• Other
• At least 4 weeks since prior and no concurrent participation in another experimental drug trial
• No concurrent full-dose anticoagulation
• No concurrent experimental drugs